{
    "clinical_study": {
        "@rank": "104142", 
        "arm_group": {
            "arm_group_label": "IPI-145 and [14C] IPI-145", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, 2-period, absorption, distribution, metabolism and excretion (ADME)\n      and absolute bioavailability study in 6 healthy adult male subjects."
        }, 
        "brief_title": "IPI-145 ADME and Absolute Bioavailability Study", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "In Period 1, subjects will receive a single oral dose of 25 mg IPI-145, followed by a\n      15-minute IV infusion of approximately 2.8 \u03bcg 14C-IPI-145 containing 14.8 kBq of\n      radioactivity.\n\n      In Period 2, the same subjects will receive a single dose of 25 mg 14C-IPI-145 as an oral\n      suspension, containing approximately 3.15 MBq of radioactivity.\n\n      There will be a washout period of at least 14 days between Period 1 and Period 2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males, between 18 and 45 years of age, inclusive Body Mass Index (BMI) : 18.0-30.0\n             kg/m2\n\n          -  In good health, determined by no clinically significant findings from medical\n             history, physical examination (Check-in), 12-lead ECG, and vital signs\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures\n\n        Exclusion Criteria:\n\n          -  Evidence of clinically significant medical conditions\n\n          -  History of gastrointestinal surgery that may affect drug absorption\n\n          -  Positive or indeterminate QuantiFERON-TB Gold test at screening\n\n          -  Any active infection at the time of screening or admission\n\n          -  Participation in another ADME study with a radiation burden >0.1 mSv in the period of\n             1 year before screening\n\n          -  Irregular defecation pattern (less than once per 2 days)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836861", 
            "org_study_id": "IPI-145-05", 
            "secondary_id": "2012-005425-75"
        }, 
        "intervention": {
            "arm_group_label": "IPI-145 and [14C] IPI-145", 
            "description": "Intravenous infusion: approximately 2.8 \u03bcg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145", 
            "intervention_name": "IPI-145", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Phase I", 
            "healthy male volunteers", 
            "ADME", 
            "Bioavailability", 
            "PI3K inhibitor", 
            "Absorption", 
            "Distribution", 
            "Metabolism", 
            "Excretion", 
            "bioavailability", 
            "safety"
        ], 
        "lastchanged_date": "May 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands"
                }, 
                "name": "Pharmaceuticals Research Association (PRA)"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label Study of the Absorption, Distribution, Metabolism and Excretion of 14C-Labeled IPI-145 and the Absolute Bioavailability of IPI-145 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Pharmaceuticals Research Association (PRA), BV", 
            "last_name": "Jan-Jaap van Lier, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "PK parameters (AUC) of IPI-145 in plasma", 
                "safety_issue": "No", 
                "time_frame": "over 48 hours"
            }, 
            {
                "measure": "PK parameters (AUC) and radioactivity excreted in urine and feces", 
                "safety_issue": "No", 
                "time_frame": "over 144 hours"
            }, 
            {
                "measure": "PK parameters (Cmax) of IPI-145 in plasma", 
                "safety_issue": "No", 
                "time_frame": "over 48 hours"
            }, 
            {
                "measure": "PK parameters (t1/2) of IPI-145 in plasma", 
                "safety_issue": "No", 
                "time_frame": "over 48 hours"
            }, 
            {
                "measure": "PK parameters (Cmax) and radioactivity excreted in urine and feces", 
                "safety_issue": "No", 
                "time_frame": "over 144 hours"
            }, 
            {
                "measure": "PK parameters (t1/2) and radioactivity excreted in urine and feces", 
                "safety_issue": "No", 
                "time_frame": "over 144 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events following a single dose administration of IPI-145", 
            "safety_issue": "No", 
            "time_frame": "over 4 weeks"
        }, 
        "source": "Infinity Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Infinity Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}